Evidence mapPaperPMID 41511735Full record

ReviewCurrent medical science2026

Toward an Integrated Therapeutic Approach for Familial Hypercholesterolemia.

Acharya Balkrishna, Upasana Agarwal, Sugandh Saxena, Gunjan Sharma, Vedpriya Arya

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Acharya BalkrishnaPatanjali Herbal Research Division, Patanjali Research Foundation, Haridwar, Uttarakhand, 249404, India.
Upasana AgarwalPatanjali Herbal Research Division, Patanjali Research Foundation, Haridwar, Uttarakhand, 249404, India. upasana.agarwal@patanjali.res.in.ORCID http://orcid.org/0000-0003-3717-7611
Sugandh SaxenaPatanjali Herbal Research Division, Patanjali Research Foundation, Haridwar, Uttarakhand, 249404, India.
Gunjan SharmaPatanjali Herbal Research Division, Patanjali Research Foundation, Haridwar, Uttarakhand, 249404, India.
Vedpriya AryaPatanjali Herbal Research Division, Patanjali Research Foundation, Haridwar, Uttarakhand, 249404, India.

Funding

Ministry of AYUSH, Government of India F. No. Ad-35013/4/2022-KPMG-NMCG
6 · The paper itself

Abstract

Familial hypercholesterolemia (FH) is a heritable condition that disrupts the body's ability to clear low-density lipoprotein cholesterol (LDL-C), commonly known as "bad cholesterol" from the bloodstream. This leads to persistently elevated LDL levels from birth, significantly increasing the risk of premature atherosclerosis and cardiovascular events, such as heart attack and stroke. This occurs due to variations in genes such as low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9). The treatments that are available for FH include pharmacological interventions, microbiome-based treatments, molecular approaches, nanotechnology methods, surgical procedures, nutraceuticals, herbal therapy, yoga and physical fitness methods, along with lifestyle management. This review discusses the adverse effects associated with various conventional treatment methods for hypercholesterolemia and the need for a safe and effective approach for the treatment of this genetic condition. An integrated approach combining pharmacological, molecular, and lifestyle interventions has emerged as a pragmatic solution. Yoga and fitness-based therapies positively impact lipid profiles, offering non-pharmacological and holistic adjunctive options. This comprehensive approach addresses the multifaceted aspects of FH management, considering genetic factors, socioeconomic considerations, and individualized patient needs.

Indexed as

Hyperlipoproteinemia Type IIApolipoproteins BCholesterol, LDLHumansLife StyleProprotein Convertase 9Receptors, LDLYogaApolipoproteins BCholesterol, LDLLDLR protein, humanPCSK9 protein, humanProprotein Convertase 9Receptors, LDLFamilial hypercholesterolemiaGene therapyHerbal medicineIntegrative medicineLipoprotein aphersisPCSK9 inhibitorsStatinsYoga therapy

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.